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ORIGINAL ARTICLES
Effect of enalapril on myocardial
infarction and unstable angina in patients with
low ejection fractions
An association between raised renin levels and
myocardial infarction has been reported. We studied
the effects of enalapril, an angiotensin-converting
enzyme (ACE) inhibitor, on the development of
myocardial infarction and unstable angina in 6797
patients with ejection fractions &le;0&middot;35 enrolled into
the two Studies of Left Ventricular Dysfunction
(SOLVD) trials.
Patients were randomly assigned to placebo
(n=3401) or enalapril (n=3396) at doses of
2&middot;5-20 mg per day in two concurrent double-blind
trials with the same protocol. Patients with heart
failure entered the treatment trial (n=2569) and
those without heart failure entered the prevention
trial (n=4228). Follow-up averaged 40 months. In
each trial there were significant reductions in the
number of patients developing myocardial infarction
(treatment trial: 158 placebo vs 127 enalapril,
P<0&middot;02; prevention trial: 204 vs 161 p<0&middot;01) or
unstable angina (240 vs 187 p<0&middot;001; 355 vs 312,
p<0&middot;05). Combined, there were 362 placebo group
patients with myocardial infarction compared with
288 in the enalapril group (risk reduction 23%, 95%
Cl 11-34%; p<0&middot;001). 595 placebo group patients
developed unstable angina compared with 499 in
the enalapril group (risk reduction 20%, 95% Cl
9-29%, p<0&middot;001). There was also a reduction in
cardiac deaths (711 placebo, 615 enalapril;
P<0&middot;003), so that the reduction in the combined
endpoint of deaths, myocardial infarction, and
unstable angina was highly significant (20% risk
reduction, 95% Cl 14-26%; p<0&middot;0001).
Enalapril treatment significantly reduced
myocardial infarction, unstable angina, and cardiac
mortality in patients with low ejection fractions.
Lancet 1992; 340: 1173-78.
Introduction
Atherosclerosis and its acute clinical sequelae such as
myocardial infarction are caused by multiple risk factors.!
There is a consensus that by tackling risk factors (eg, by not
smoking2 and by lowering low-density lipoprotein
cholesterol), and by using antiplatelet agents or beta-
blockers the probability of myocardial infarction will be
reduced. A retrospective analysis of hypertensive patients
suggested that high renin levels may predict myocardial
infarction or stroke6 and a prospective study of 1717
hypertensive patients reported that a high renin profile was
associated with higher rates of both myocardial infarction
and death? However, it is not clear whether the increases in
ADDRESSES: National Heart, Lung, and Blood Institute,
Bethesda, Maryland, USA (S. Yusuf, FRCP); University of Florida,
Gainesville (C J. Pepine, MD); University of North Carolina,
Chapel Hill (C. Garces, MSc); University of Louvain, Belgium (H.
Pouleur, MD, M. Rousseau, MD); New England Medical Center,
Boston (D. Salem, MD); Robert Wood Johnson Medical Center,
New Brunswick, New Jersey (J Kostis, MD); University of Texas
Medical Center, Houston (C. Benedict, MD); Montreal Heart
Institute, Canada (M. Bourassa, MD); and University of
Michigan, Ann Arbor (B Pitt, MD). Correspondence to Dr Salim Yusuf,
Division of Cardiology, Room 614, McMaster Clinic, Hamilton General
Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada.
1174
plasma renin reflected the extent of underlying myocardia
dysfunction secondary to advanced coronary atherosclerosi
or whether stimulation of the renin-angiotensin system wa
directly involved in the pathogenesis of myocardia
infarction. This can be best clarified by a large randomise(
placebo controlled study of angiotensin-converting enzym
(ACE) inhibition.
The Studies of Left Ventricular Dysfunction (SOLVD
trials provide an opportunity to assess whether use of ai
ACE inhibitor reduces the risk of myocardial infarction o:
unstable angina.8 These two randomised trials wen
designed to assess the effect of enalapril versus placebo it
patients with a low ejection fraction. Patients with over
heart failure requiring treatment with diuretics, digitalis, o:
vasodilators other than ACE inhibitors were enrolled int(
the treatment trial; and those without overt heart failure anc
not requiring therapy for this condition were entered int(
the prevention trial. The results from both trials, related t(
the main endpoints of mortality and hospital admission fo]
heart failure, have been reported.1,10 Data wer(
prospectively and systematically collected on myocardia
infarction (a predefined secondary endpoint) and or
unstable angina and form the basis of this report.
Patients and methods
Organisation
Eligible patients were randomly assigned to treatment group
separately at 83 hospitals linked to twenty-three centres in the US,
Canada, and Belgium. Data were analysed centrally at the
coordinating centre (University of North Carolina). The project
office was located in the Clinical Trials Branch, National Heart,
Lung and Blood Institute. A steering committee, consisting oj
principal investigators from the centre and the project office
developed and implemented the protocol. An independent data and
safety monitoring board evaluated the progress of the study. The
study was approved by the institutional review board of the
hospitals concerned and all patients provided written informed
consent.
Eligibility, run-in period and randomisation
Patients with ejection fractions of 0-35 or less were eligible for
either trial. Details of the measurement of ejection fraction,
exclusion criteria, screening, and run-in periods have been
published.8 Patients were ineligible if they had had acute myocardial
infarction during the preceding 30 days, were admitted to hospital
for unstable angina, or had had a revascularisation procedure in the
previous 6 months. During the run-in period all patients received
2-5 mg enalapril twice daily for 2-7 days. This was followed by 2
weeks on equivalent placebo. Patients with no need for heart failure
therapy at the end of that time were entered into the prevention trial;
those requiring treatment for heart failure at entry were entered into
the treatment trial. Patients were randomised to enalapril (2-5 mg
twice daily, titrated up to 10 mg twice daily) or matching placebo.
Patients were then seen at 2 weeks, 6 weeks, at 4 months and then
every 4 months until the end of the study.
Follow-up and outcome measures
At the time of this report, the vital status of 8 of 3401 patients in
the enalapril group and 2 of 3396 patients in the placebo group was
unknown. Causes of death and reasons for hospital admission were
classified by the principal investigator on standard forms without
knowledge of treatment assignment. A definite myocardial
infarction was considered present if the investigator had identified
this complication on a standard form or if a death certificate
indicated a fatal myocardial infarction. Documentation on the
criteria for this diagnosis-namely characteristic chest pain, typical
electrocardiographic changes, and typical enzyme changes-was
required. A myocardial infarction was considered to have been a
Months
Fig 1-Cumulative incidence of myocardial infarction,
combined trials.
fatal one if the patient died within 7 days of onset of symptoms.
Unstable angina was defined as new onset or worsening angina
pectoris requiring hospital admission, and this was based on the
discharge diagnosis. Patients who had angina and were admitted for
an investigation were not included in this category.
Statistical analyses
Although there was an expectation that lowering blood pressure
by an ACE inhibitor might lower coronary-heart-disease events
there were also concerns that lowering blood pressure in
normotensive individuals may increase the risk of cardiovascular
events ("J-shaped curve"),’1 so two-sided tests have been used in
statistical analyses. A stratified log-rank test was used to compare
life-table curves for patients randomly assigned to the two groups."
The percentage reduction in events was reported as (1-RR) x 100,
where RR is the estimated relative risk of an event in the enalapril
group as compared with the placebo group estimated from life
tables. Uniformity of treatment effects across subgroups was
assessed by the likelihood-ratio test on the basis of the proportional
hazards model. 13 Detailed data are provided separately for each trial
and in combination in tables I and n. Given the consistency of the
results in both trials, the text deals primarily with the overall data.
Analysis of the impact of interim ischaemic events on prognosis was
based on a time-dependent covariate analysis that adjusted for
several prognostic factors (eg, ejection fraction, age, New York
Heart Association functional class) and for trial and treatment
allocation.
Results
From June, 1986, to April, 1990, 6797 patients were
enrolled. Of these 2569 entered the treatment trial and 4228
patients the prevention trial. The clinical characteristics
have been described.9no Follow-up ranged from 15 to 62
months (average 40).
Myocardial infarction (fig 1) 
Table I provides details on rates of fatal and non-fatal
myocardial infarction separately and in combination with
cardiac and total mortality. Risk reductions for myocardial
infarction were similar in both trials (23% in the treatment
trial, p < 002; 24% in the prevention trial, p < 0-01). At the
end of the two trials, 362 (10-6%) patients in the placebo
group had had a myocardial infarction compared with 288
(8-5%) in the enalapril group (risk reduction 23%, 95%
interval [CI] 11-34%; p < 0-001). The reduction in non-
fatal myocardial infarction appeared to be larger (29%) than
the reduction in fatal myocardial infarction (14%), but the
CIs of these estimates overlap substantially and provide no
evidence of heterogeneity.
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TABLE I-EFFECT OF ENALAPRIL ON DEVELOPMENT OF MYOCARDIAL INFARCTION, HOSPITALISATION FOR WORSENING ANGINA,
AND CARDIAC AND TOTAL MORTALITY
I I I I
*Data for hospitalisation for angina mclude both primary and secondary discharge diagnosis. Numbers of patients hospitalised with a primary diagnosis of worsening angma are.
prevention trial (329 placebo, 296 enalapril, Z=1 -61), treatment trial (204 placebo, 166enalapril, Z=2 55) and combmed trials (533 placebo, 462 enlaprll, Z=2 84)
Ml=myocardial infarction
173 patients (98 placebo, 75 enalapril) died with a
diagnosis of myocardial infarction without being admitted
to hospital. Of the 477 patients admitted with a diagnosis of
myocardial infarction, documentation of diagnostic criteria
was available in 472 (98-9%) (263 placebo, 109 enalapril).
445 (94%) met two or all three diagnostic criteria (249
placebo, 196 enalapril) and 27 had only one criterion
checked (14 placebo, 13 enalapril).
Unstable angina (fig 2)
Significant reductions in admissions for unstable angina
were observed in the treatment trial (240 placebo, 187
enalapril; p < 0-001) and in the prevention trial (355 placebo,
312 enalapril; p < 0-05) (table l). Thus 595 (17-5%) patients
in the placebo group were admitted for unstable angina
compared with 499 (14-7%) in the enalapril group (risk
reduction 20%, 95% CI 9-29%; p < 0-001).
Cardiac death, myocardial infarction, admission for angina
(fig 3)
Similar reductions in both myocardial infarction and
angina were observed. 859 (25-3%) patients in the placebo
group and 707 (20-8%) in the enalapril group had a
myocardial infarction or were admitted for angina (risk
Months




Fig 3-Cumulative incidence of cardiac death, myocardial
infarction, or unstable angina, combined trials.
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TABLE II-EFFECT OF ENALAPRIL OR PLACEBO ON MYOCARDIAL INFARCTION OR HOSPITALISATION FOR ANGINA BY BASELINE
CHARACTERISTICS IN COMBINED TRIALS
*For heterogeneity of effects in subgroups Ejection fraction, median =28; Age, median= 61. CABG= coronary artery bypass graft Ca= calcium
reduction 22%, 95% CI of 14-29%, p < 00001). Cardiac
mortality was greater in the placebo group (711 deaths,
21 %) than in the enalapril group (615 deaths, 18%). The
risk reduction was 17% (95% CI 7 to 25; p < 0001). For the
combined end-point of cardiac death, infarction, or
hospitalisation for angina, the differences are highly
significant. 1350 or 39-7% in the placebo group; 1117 or
32-9% in the enalapril group). The risk reduction for this
combined end-point was 22% (95% CI 16-28%;
p < 00001) (fig 3), and was the same in treatment (23%,
95% CI 13-32%; p<0001) and in the prevention (23%,
95% CI 11-33%; p < 0-001) trials.
Time course of effects (figs 1 and 2)
During the first 3 months after randomisation there was
little difference in the incidence of either myocardial
infarction or hospital admission for angina. Non-significant
trends towards fewer such events in the enalapril group were
apparent at 6 months for both events. Thereafter the
differences between the enalapril and placebo groups
continued to widen.
Effects in subgroups (table II)
Before examination of the effects of treatment in
subgroups, baseline characteristics that might influence the
results were identified. These were the aetiology of
underlying cardiac disease (ischaemic, hypertension, other
causes), concomitant drug use (nitrates, antiplatelet drugs,
beta-blockers, calcium blockers), prior coronary artery
bypass graft surgery, entry blood pressure, and presence or
absence of angina. Analyses were also done on the basis of
ejection fraction and functional status, although there was
no prior expectation of the treatment effect varying in these
subgroups.
There appeared to be no heterogeneity of effect of
enalapril on myocardial infarction among most of the
various subgroups examined. However, the reduction in
myocardial infarction and unstable angina was significantly
greater among those with angina at entry into the study.
There also appeared to be greater benefit among those
without prior ischaemic heart disease. However, these
subgroup analyses should be cautiously interpreted and
need independent confirmation.
Blood pressure (table III)
Systolic and diastolic BP were significantly lower in the
patients randomly assigned to enalapril than in the placebo
group, by 6 and 4 mm Hg respectively. A significantly lower
BP was seen as early as the first post-randomisation visit, 2
weeks after starting therapy (125/77 mm Hg placebo, 119/74
mm Hg enalapril); and this difference persisted. There were
no differences in heart rate between the two groups at
baseline or follow-up. To evaluate the results by degree of
BP reduction while preserving the randomised
comparisons, the BP decline at the end of 7 days of therapy
with enalapril before randomisation was compared with BP
reduction 6 weeks and 4 months after randomisation in the
enalapril group. This demonstrated a modest correlation
TABLE III-EFFECT OF BASELINE BP OR BP REDUCTION
(RESPONSE TO 25 MG ENALAPRIL BEFORE RANDOMISATION)
ON REDUCTION IN ISCHAEMIC EVENTS IN COMBINED TRIALS
SBP=systolic, DBP=diastolic BP, MI=myocardial mfarction Angma=hosprtal
admission for worsening angina
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Fig 4-Risk of death in patients who develop myocardial infarction (MI) (left hand panel) or unstable
angina (right hand panel) compared with patients in whom those events did not develop.
(r=0’52 systolic, r = 0-54 diastolic) at 6 weeks, with almost
identical correlations at 4 months. Patients were then
divided into two groups (above and below the median) based
upon the degree of BP pressure reduction after the run-in
period. There was a trend towards larger reductions in
myocardial infarction and unstable angina among those with
a greater reduction in systolic and diastolic BP pressures,
although the test for interaction was not significant (table 11).
Risk reductions in myocardial infartion and unstable angina
were similar in patients with baseline BP above and below
124 mmHg systolic or 80 mm Hg diastolic.
Prognostic impact of interim myocardial infarction
or unstable angina
Among 650 patients with a myocardial infarction during
the study the 1-year mortality rate was 55-4% compared
with 7-3% among the 6147 patients without myocrdial
infarction (adjusted relative risk (RR) z8, 95% CI 6-9-8-8)
(fig 4). 25% of all deaths in the study were preceded by an
interim myocardial infarction. Even after exclusion of
deaths during the first 7 days after an infarction, mortality
was higher in those who had an interim infarction (RR 3-5,
95% CI 2-9-4-2). The 12-month rates of hospital admission
for heart failure were 20-5% and 8-6% respectively (RR2-1,
95% CI 1-6-2-6). For the 1094 patients with unstable
angina, the 1-year mortality rate was 14-6% compared to
90% among the 5703 patients without unstable angina (RR
1-4,95% CI 1-2-1-6) (fig 4). The 1-year rates of hospital
admission were 15-3% and 8-4%, (RR 1-6, CI 1-4-1-9).
34% of all deaths in the study were preceded by an interim
myocardial infarction or hospital admission for unstable
angina.
Discussion
This study demonstrated, in both trials, significant
reductions in myocardial infarction, unstable angina, and
cardiac mortality in patients with low ejection fractions
treated with the ACE inhibitor enalapril plus conventional
therapy. Enalapril reduced the risk of major ischaemic
events by about 22%. Previous reports from SOLVD9’o
and the Cooperative North Scandinavian Enalapril Survival
Study14 demonstrated reductions in deaths from and
hospital admissions for heart failure with ACE inhibitor
therapy. Development of myocardial infarction and
unstable angina greatly increased the risk of death and
hospital admission for heart failure. Our latest data show
that prevention of major ischaemic events should be an
integral part of the management of patients with heart failure
or left-ventricular dysfunction.
Myocardial infarction was a secondary endpoint specified
in the protocol; hospital admission for angina was not and
there are no objective criteria for the diagnosis of unstable
angina, so data on this endpoint should be cautiously
interpreted. However, the differences observed in unstable
angina are likely to be unbiased because the diagnosis was
made blind and the data were collected prospectively on
standard forms. The reduction in unstable angina was
significant in each trial and the combined data from both
trials are highly significant. The reduction in unstable
angina is supported by a reduction in myocardial infarction
as both of these outcomes are likely to have some similarities
in their pathogenesis. Previous small trials reported
conflicting results on the effect of ACE inhibitors on the
severity of stable angina pectoris.15,16 In some previous
studies there was benefit, whereas in others there was either
no effect or an exacerbation of angina. However, all previous
studies have been small and lasted only 6 weeks to 3 months,
and none evaluated impact on unstable angina or infarction.
In our study, reductions in unstable angina and myocardial
infarction were not apparent until at least 6 months.
Thereafter, the rates of these events were significantly
reduced. This contrasts with the reduction in hospital
admission for worsening heart failure with enalapril which
was observed shortly after randomisation and was much
reduced by 6 months. This suggests that the beneficial
effects of enalapril on ischaemic events were unlikely to be
due to an immediate effect such as reduction in myocardial
oxygen demand by an effect on preload and afterload (as
seen with beta-blockers)5 or an effect on coagulation factors
(as seen with antiplatelet agents4 or anticoagulants.l’ The
delay in the reduction of ischaemic events resembles the
pattern observed in trials of cholesterol lowering. 18
The mechanisms that may have led to the observed
differences in myocardial infarction and major ischaemic
events are not clear. Several studies have demonstrated a
continuous association between raised BP and increased risk
of myocardial infarction even among people with diastolic
BP below 90 mm Hg.19 An overview indicates that a 5 mm
Hg or so difference in diastolic BP is associated with a 21 %
difference in incidence of coronary heart disease events. In
previous trials of antihypertensive therapy, a 5-6 mm Hg
reduction in diastolic BP was associated with a 14%
reduction in coronary heart disease events.2&deg; In our trial the
difference in diastolic BP was 4 mm Hg, yet we observed a
23% reduction in myocardial infarction. Therefore, the
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benefits we observed may only be partly explained by the
reductions in BP.
However, there are important differences in patient
selection between our trial (normotensive high-risk
individuals with pre-existing cardiac damage) and the trials
of antihypertensive therapy (patients with higher BP but
few with obvious cardiac damage). In SOLVD the entry BP
was 125/77 mm Hg which is considered to be in the normal
range; and a 4 mm Hg reduction was associated with fewer
ischaemic events. Furthermore, these benefits were
observed even among those with initial BP below 124/80
mm Hg and among those with the greatest reductions in BP.
Extrapolation of these data suggest that lowering diastolic
BP below 90 mm Hg in high-risk individuals may not be
harmful and likely to be even beneficial.
Another intriguing possibility is that ACE inhibitors may
block some of the direct adverse effects of angiotensin-II on
the coronary circulation and myocardium. Gavras et al have
reported that infusion of large doses of angiotensin-11
resulted in myocardial infarction in 6 out of 7 rabbits.21
Alderman et al have reported that hypertensive patients with
high-renin profiles have a higher risk of myocardial
infarction.7 Our data support the possibility that enalapril
had a favourable effect in reducing cardiac ischaemia and
infarction by reducing angiotensin-Il levels. Angiotensin-11
can adversely affect the balance between increased cardiac
oxygen demand and supply by either a direct coronary
vasoconstrictor effect22 or by increased inotropy by its ability
to raise cytosolic Ca2+ concentration in the myocardium.23
In addition, angiotensin-II regulates proto-oncogenes that
control cell growth and differentiation involved in both the
vascular wall and myocardium.23.24 Prolonged use of ACE
inhibitors restores normal endothelial function and vascular
dilatation in animal models of heart failure and prevents the
proliferative response to vascular injury. 23.26 It is therefore
likely that reduction in ischaemic events observed may be
due to multiple beneficial effects of an ACE inhibitor that
include BP lowering, coronary vasodilatation, an
antiproliferative effect on vascular smooth muscle,
prevention of atherosclerosis progression and myocardial
hypertrophy, and favourable effects on endothelial function.
Although our data are based on patients with low ejection
fraction, the observation of benefit in subgroups defined by
level of ejection fraction, aetiology, and against a
background of different drugs raises the possibility of a
wider role for ACE inhibitors in preventing major ischaemic
events in other populations. This hypothesis should be
tested in trials of patients with hypertension or other risk
factors that predispose to infarction and among patients with
ischaemic heart disease and preserved ventricular function.
A list of SOLVD investigators and centres -has been publishes.9 The study
was largely funded by the US National Heart, Lung and Blood Institute with
additional contributions from Merck, Sharpe and Dohme, which had no
involvement in the design, conduct, analysis, or interpretation of the data.
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